Bayer leads the Series B financing of Senti Bio

Senti Bio receives 105 million US dollars. The financing round was led by Bayer.
Senti Biosciences receives an investment of 105 million US dollars. Among the investors is Leaps by Bayer, the investment arm of Bayer AG. The San Francisco-based start-up is working on new biological techniques to improve cell and gene therapies.
"We believe that synthetic biology will become an important pillar in next-generation cell and gene therapy and that Senti Bio's leadership in developing and optimizing biological circuits fits perfectly with our goal of preventing and curing cancer and regenerating lost tissue function," says investor Jürgen Eckhardt of Bayer. Senti Bio plans to start a pre-clinical study this year.

Newsletter
Startups, stories and stats from the German startup ecosystem straight to your inbox. Subscribe with 2 clicks. Noice.
LinkedIn ConnectFYI: English edition available
Hello my friend, have you been stranded on the German edition of Startbase? At least your browser tells us, that you do not speak German - so maybe you would like to switch to the English edition instead?
FYI: Deutsche Edition verfügbar
Hallo mein Freund, du befindest dich auf der Englischen Edition der Startbase und laut deinem Browser sprichst du eigentlich auch Deutsch. Magst du die Sprache wechseln?